Table 2 Univariable analyses of overall survival (OS) and progression free survival (PFS) after first AHCT, overall and stratified by relevant risk factors.

From: In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

 

Group

PFS

OS

  

N

3 y (95% CI)

P

N

3 y (95% CI)

P

Overall

 

4300

49% (47–51%)

 

4388

84% (83–85%)

 

Conditioning at AHCT

Vel-Mel

285

46% (39–52%)

0.06

292

76% (71–82%)

<0.001

Mel200

4015

49% (47–51%)

 

4096

85% (83–86%)

 

Age at AHCT

<50

704

49% (44–53%)

0.9

721

85% (81–88%)

0.4

50–64

2929

49% (47–51%)

 

2989

84% (83–86%)

 

65+

667

49% (44–54%)

 

678

82% (78–86%)

 

ISS

I

922

55% (51–59%)

<0.001

926

91% (88–93%)

<0.001

II

672

48% (43–53%)

 

682

84% (80–87%)

 

III

536

39% (34–44%)

 

545

78% (73–82%)

 

Karnofsky at AHCT

<90

1282

48% (45–52%)

0.2

1312

82% (79–84%)

0.006

90–100

2743

49% (47–51%)

 

2791

85% (83–86%)

 

Cytogenetics

standard

1264

50% (47–54%)

<0.001

1275

87% (85–89%)

<0.001

high

311

39% (32–46%)

 

314

77% (71–83%)

 

Ig

IgG

2194

50% (47–52%)

0.06

2229

85% (83–87%)

0.1

IgA

743

45% (41–50%)

 

751

81% (77–85%)

 

IgD/M/E

104

54% (43–66%)

 

105

85% (76–93%)

 

Response at AHCT

CR/VGPR

2564

54% (51–56%)

<0.001

2607

86% (84–87%)

0.002

<=PR

1687

43% (40–46%)

 

1728

82% (80–84%)

 

Light chain

kappa

2727

50% (48–53%)

0.02

2782

86% (84–88%)

<0.001

lambda

1443

47% (43–50%)

 

1474

80% (77–82%)

 

Non-secretory

50

62% (46–78%)

 

51

85% (72–97%)

 
  1. Three-year Kaplan Meier estimates are given, with group differences evaluated by means of logrank tests. All estimates are reported with 95% confidence intervals in parentheses.
Back to article page